Johnson & Johnson Unveils Details On Ottava Soft-Tissue Robot, Chasing Intuitive, Medtronic
Executive Summary
J&J said its Ottava robotic platform has six robotic arms, “zero footprint,” and can be used for various procedures.
You may also be interested in...
Fly Me To The Moon: French Company 'Empowers' Surgeons With Maestro
The Paris-based company has developed Maestro, a lightweight robotic assistant for use in laparoscopic procedures.
News We’re Watching – FDA Nixes Neuralink Trials, Layoffs at J&J, Novel Knee Implants
This week, we learned that the US FDA thinks Elon Musk’s Neuralink brain interface device isn’t ready for human trials. Additionally, J&J cut about 300 medtech jobs, Stryker launched a knee implant, and Active Implants’ meniscus replacement device made it to the FDA’s advisory panel calendar.
J&J Pushes Back Launch Of Ottava Robotic Platform By Two Years
The company originally expected the first-in-human trial of the soft-tissue robotic surgery system to begin in late 2022 and reach the market by 2023, but the company now expects those trials to begin in 2024.